Alteogen signed a contract with AstraZeneca when did this happen and what were the terms
ChatGPT said:
As of my current knowledge, there is no publicly available information indicating that Alteogen has signed a direct contract with AstraZeneca. However, in November 2024, Alteogen entered into an exclusive license agreement with Daiichi Sankyo to develop and commercialize a subcutaneous (SC) version of Enhertu (fam-trastuzumab deruxtecan-nxki), an antibody-drug conjugate (ADC) jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.
NASDAQ.COM
Under the terms of this agreement, Daiichi Sankyo acquired worldwide rights to use Alteogen's proprietary hyaluronidase enzyme, ALT-B4, to develop the SC formulation of Enhertu. Alteogen received an upfront payment of $20 million and is eligible for up to $280 million in additional payments upon achieving specified development, regulatory, and sales milestones. Additionally, Alteogen is entitled to receive tiered royalties on the sales of the commercialized product.
NASDAQ.COM
This collaboration aims to provide a new administration route for Enhertu, potentially allowing patients to receive the treatment outside of clinical settings, thereby enhancing convenience and accessibility.
Market Data 
Markets 
AI
